FRI0233 Real-World Treatment Persistence and Clinical Outcomes of TNFI Cycling vs Switching To New Mechanism-of-Action Dmards among Patients with Rheumatoid Arthritis in The United States

Abstract

BackgroundRecent studies suggested that in rheumatoid arthritis (RA) patients discontinuing their prior tumor necrosis factor inhibitor (TNFi), treatment persistence was greater in those switching to a disease-modifying antirheumatic drug (DMARD)...